These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36034778)

  • 1. Pan-cancer analyses identify DCBLD2 as an oncogenic, immunological, and prognostic biomarker.
    Xie P; Liu JY; Yan H; Wang ZB; Jiang SL; Li X; Liu ZQ
    Front Pharmacol; 2022; 13():950831. PubMed ID: 36034778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptomic Profiling Identifies DCBLD2 as a Diagnostic and Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma.
    Feng Z; Li K; Wu Y; Peng C
    Front Mol Biosci; 2021; 8():659168. PubMed ID: 33834039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discoidin, CUB and LCCL domain-containing protein 2 (DCBLD2) is a novel biomarker of myxofibrosarcoma invasion identified by global protein expression profiling.
    Kikuta K; Kubota D; Yoshida A; Qiao Z; Morioka H; Nakamura M; Matsumoto M; Chuman H; Kawai A; Kondo T
    Biochim Biophys Acta Proteins Proteom; 2017 Sep; 1865(9):1160-1166. PubMed ID: 28668639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DCBLD2 deletion increases hyperglycemia and induces vascular remodeling by inhibiting insulin receptor recycling in endothelial cells.
    Guo L; Zong Y; Yang W; Lin Y; Feng Q; Yu C; Liu X; Li C; Zhang W; Wang R; Li L; Pei Y; Wang H; Liu D; Niu H; Nie L
    FEBS J; 2024 Jun; ():. PubMed ID: 38872483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic multi-site phosphorylation by Fyn and Abl drives the interaction between CRKL and the novel scaffolding receptors DCBLD1 and DCBLD2.
    Schmoker AM; Weinert JL; Kellett KJ; Johnson HE; Joy RM; Weir ME; Ebert AM; Ballif BA
    Biochem J; 2017 Nov; 474(23):3963-3984. PubMed ID: 29025973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic down-regulation and suppressive role of DCBLD2 in gastric cancer cell proliferation and invasion.
    Kim M; Lee KT; Jang HR; Kim JH; Noh SM; Song KS; Cho JS; Jeong HY; Kim SY; Yoo HS; Kim YS
    Mol Cancer Res; 2008 Feb; 6(2):222-30. PubMed ID: 18314483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DCBLD2 Mediates Epithelial-Mesenchymal Transition-Induced Metastasis by Cisplatin in Lung Adenocarcinoma.
    Chen X; Lv Y; Xu K; Wang X; Zhao Y; Li J; Qin X; Shi Y; Wang L; Chang A; Huang C; Xiang R
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33808696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transmembrane protein DCBLD2 is correlated with poor prognosis and affects phenotype by regulating epithelial-mesenchymal transition in human glioblastoma cells.
    Cheng S; Wang LY; Wang CH; Wang FK; Zhu B; Zhang P; Wang GH
    Neuroreport; 2021 Apr; 32(6):507-517. PubMed ID: 33788813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DCBLD2 Affects the Development of Colorectal Cancer via EMT and Angiogenesis and Modulates 5-FU Drug Resistance.
    Xie P; Yuan FQ; Huang MS; Zhang W; Zhou HH; Li X; Liu ZQ
    Front Cell Dev Biol; 2021; 9():669285. PubMed ID: 34095137
    [No Abstract]   [Full Text] [Related]  

  • 10. Association of DCBLD2 upregulation with tumor progression and poor survival in colorectal cancer.
    He J; Huang H; Du Y; Peng D; Zhou Y; Li Y; Wang H; Zhou Y; Nie Y
    Cell Oncol (Dordr); 2020 Jun; 43(3):409-420. PubMed ID: 32166582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic analysis of the long noncoding RNA (lncRNA)-miRNA-mRNA competing endogenous RNA network to identify prognostic biomarkers and the potential regulatory axis in glioblastoma multiforme.
    Li X; Chen R; Ren C; Huang A; Ding W; Wang H
    Transl Cancer Res; 2021 Nov; 10(11):4739-4755. PubMed ID: 35116328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.
    Feng H; Lopez GY; Kim CK; Alvarez A; Duncan CG; Nishikawa R; Nagane M; Su AJ; Auron PE; Hedberg ML; Wang L; Raizer JJ; Kessler JA; Parsa AT; Gao WQ; Kim SH; Minata M; Nakano I; Grandis JR; McLendon RE; Bigner DD; Lin HK; Furnari FB; Cavenee WK; Hu B; Yan H; Cheng SY
    J Clin Invest; 2014 Sep; 124(9):3741-56. PubMed ID: 25061874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The DCBLD receptor family: emerging signaling roles in development, homeostasis and disease.
    Schmoker AM; Ebert AM; Ballif BA
    Biochem J; 2019 Mar; 476(6):931-950. PubMed ID: 30902898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DCBLD2 gene variations correlate with nasal polyposis in Korean asthma patients.
    Pasaje CF; Bae JS; Park BL; Cheong HS; Kim JH; Jang AS; Uh ST; Park CS; Shin HD
    Lung; 2012 Apr; 190(2):199-207. PubMed ID: 22261696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.
    Wei C; Wang B; Peng D; Zhang X; Li Z; Luo L; He Y; Liang H; Du X; Li S; Zhang S; Zhang Z; Han L; Zhang J
    Front Immunol; 2022; 13():849592. PubMed ID: 35444654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative Pan-Cancer Analysis Confirmed that FCGR3A is a Candidate Biomarker Associated With Tumor Immunity.
    Li L; Huang Z; Du K; Liu X; Li C; Wang D; Zhang Y; Wang C; Li J
    Front Pharmacol; 2022; 13():900699. PubMed ID: 35668930
    [No Abstract]   [Full Text] [Related]  

  • 17. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.
    Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W
    Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RecQ mediated genome instability 2 (
    Wei W; Ying X; Chen L; Sun Q; Lu X; Xia Y; Xu R; Zhu Z; Zhang D; Tang Q; Li L; Xie J; Yu H
    Aging (Albany NY); 2022 May; 14(9):4107-4136. PubMed ID: 35552266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-Cancer Analysis of the Oncogenic and Immunological Role of
    Ding J; Meng Y; Han Z; Luo X; Guo X; Li Y; Liu S; Zhuang K
    Front Oncol; 2022; 12():811567. PubMed ID: 35651805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive pan-cancer analysis on CBX3 as a prognostic and immunological biomarker.
    Niu H; Chen P; Fan L; Sun B
    BMC Med Genomics; 2022 Feb; 15(1):29. PubMed ID: 35172803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.